Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms

References

• Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. (2008). Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 65 Suppl 1:60–67.
   PubMed Web of Science ®Google Scholar
• Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. (2009). Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica 39:523–533.
   PubMed Web of Science ®Google Scholar
• Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT. (2006). Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 34:384–388.
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. (2004). Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628–1640.
   PubMed Web of Science ®Google Scholar
• Bertino JS Jr, Greenberg HE, Reed MD; American College of Clinical Pharmacology. (2007). American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 47:418–422.
   PubMed Web of Science ®Google Scholar
• Boyd RA, Lalonde RL. (2007). Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 81:24–26.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Fagerholm U. (2007a). Prediction of human pharmacokinetics–evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59:803–828.
   PubMed Web of Science ®Google Scholar
• Fagerholm U. (2007b). Prediction of human pharmacokinetics–evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 59:1181–1190.
   PubMed Web of Science ®Google Scholar
• Fagerholm U. (2007c). Prediction of human pharmacokinetics–improving microsome-based predictions of hepatic metabolic clearance. J Pharm Pharmacol 59:1427–1431.
   PubMed Web of Science ®Google Scholar
• Fagerholm U. (2007d). Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J Pharm Pharmacol 59:1463–1471.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E. (1999). Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56:1–10.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150–2161.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2009). Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr Drug Metab 10:307–321.
   PubMed Web of Science ®Google Scholar
• Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, Morgan P. (2004). Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197–204.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–533.
   PubMed Web of Science ®Google Scholar
• Hyland R, Dickins M, Collins C, Jones H, Jones B. (2008). Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66:498–507.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–112.
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. (2009a). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211–223.
   PubMed Web of Science ®Google Scholar
• Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. (2009b). Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225–237.
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, Lavé T. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511–542.
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82–89.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715.
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. (2008). The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 4:1499–1506.
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. (2006). Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 80:203–215.
   PubMed Web of Science ®Google Scholar
• Lappin G, Seymour M, Young G, Higton D, Hill HM. (2011a). An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis 3:407–410.
   PubMed Web of Science ®Google Scholar
• Lappin G, Seymour M, Young G, Higton D, Hill HM. (2011b). AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis 3:393–405.
   PubMed Web of Science ®Google Scholar
• Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C. (2010). Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125–131.
   PubMed Web of Science ®Google Scholar
• Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C. (2011). Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 43:141–150.
   PubMed Web of Science ®Google Scholar
• Lappin G, Simpson M, Shishikura Y, Garner C. (2008). High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal Biochem 378:93–95.
   PubMed Web of Science ®Google Scholar
• Lin JH. (1995). Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008–1021.
   PubMed Web of Science ®Google Scholar
• Løvlie R, Daly AK, Molven A, Idle JR, Steen VM. (1996). Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30–34.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Parvez A, Gupta K. (2009). Microdosing vs. Therapeutic dosing for evaluation of pharmacokinetic data: A comparative study. J Young Pharm 1:290–294.
   Google Scholar
• Ni J, Ouyang H, Aiello M, Seto C, Borbridge L, Sakuma T, Ellis R, Welty D, Acheampong A. (2008). Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 25:1572–1582.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. (2000). A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16–35.
   PubMed Web of Science ®Google Scholar
• Prentis RA, Lis Y, Walker SR. (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25:387–396.
   PubMed Web of Science ®Google Scholar
• Robinson WT. (2008). Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin Pharmacol Ther 83:358–360.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2006). Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918–933.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148.
   PubMed Web of Science ®Google Scholar
• Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. (2010). Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298–309.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Vogel JS, Rose MJ, Ubick EA, Brunner JE, Wallace MA, Adelsberger JK, Baker MP, Henderson PT, Pearson PG, Baillie TA. (2004). Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 32:1254–1259.
   PubMed Web of Science ®Google Scholar
• Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. (1996). Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6:417–421.
   PubMedGoogle Scholar
• Theil FP, Guentert TW, Haddad S, Poulin P. (2003). Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29–49.
   PubMed Web of Science ®Google Scholar
• Thijssen HH, Baars LG. (1987). Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. J Pharmacol Exp Ther 243:1082–1088.
   PubMed Web of Science ®Google Scholar
• Turnpenny P, Fraier D, Chassaing C, Duckworth J. (2007). Development of a micro-turbulent flow chromatography focus mode method for drug quantitation in discovery bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci 856:131–140.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. (2002). Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism. Biopharm Drug Dispos 23:183–190.
   PubMed Web of Science ®Google Scholar
• Vuong le T, Ruckle JL, Blood AB, Reid MJ, Wasnich RD, Synal HA, Dueker SR. (2008). Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 97:2833–2843.
   PubMed Web of Science ®Google Scholar
• Wakenhut F, Allan GA, Fish PV, Fray MJ, Harrison AC, McCoy R, Phillips SC, Ryckmans T, Stobie A, Westbrook D, Westbrook SL, Whitlock GA. (2009). N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett 19:5078–5081.
   PubMed Web of Science ®Google Scholar
• Wakenhut F, Fish PV, Fray MJ, Gurrell I, Mills JE, Stobie A, Whitlock GA. (2008). N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors. Bioorg Med Chem Lett 18:4308–4311.
   PubMed Web of Science ®Google Scholar
• Wang YH. (2010). Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38:1094–1104.
   PubMed Web of Science ®Google Scholar
• Watson KJ, Davis J, Jones HM. (2011). Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003. Drug Metab Dispos 39:1203–1213.
   PubMed Web of Science ®Google Scholar
• Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS. (2008). Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65:680–692.
   PubMed Web of Science ®Google Scholar